Catch up on coverage from the third day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

Gold emphasized the necessity of recognizing and managing complications in aesthetic dermatology to ensure patient safety and optimal outcomes.

Denise W. Metry, MD, FAAD, explored the controversies in using lasers in infantile hemangiomas at the AAD Annual Meeting.

AbbVie’s phase 2 study demonstrates how upadacitinib reduces type 1 inflammation and boosts melanocyte biomarkers to drive vitiligo response.

Expect exciting news in the treatment of port-wine birthmarks, Kristen Marie Kelly, MD, told AAD Annual Meeting attendees.

Findings suggest that most patients on risankizumab met or exceeded the National Psoriasis Foundation’s treatment goals.

At the AAD Annual Meeting, Roy G. Geronemus, MD, emphasized the importance of early interventions for port wine stains.

Adamson dives deep into artificial intelligence, molecular testing, and melanoma overdiagnosis.

At AAD 2025, Raj Chovatiya, MD, PhD, MSCI, explored the role of social determinants in AD, HS, and PsO, emphasizing the need for improved clinical recognition and inclusive research.

Anabela Cardoso, MD, provides data on the phase 3 BRAVE-AA-PEDS trial, the largest JAK inhibitor study dedicated to adolescents with severe alopecia areata, at AAD.

Catch up on coverage from the second day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

April Armstrong, MD, MPH, FAAD, discusses her late-breaking presentation at AAD on the treatment response in patients with moderate to severe chronic CHE treated with delgocitinib.

Michael Sherling, MD, MBA, leverages AI to simplify administrative tasks and focus on patient care.

Late breaking data points to positive data for dupilumab for bullous pemphigoid.

Adamson highlighted melanoma's rising incidence and the growing concerns of overdiagnosis at AAD 2025.

Shawn Kwatra, MD, FAAD, reviews his late-breaking data presentation at AAD on the first original studies of a topical cream for prurigo nodularis.

Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream data presented at AAD 2025.

The ADORING 3 study demonstrated that tapinarof cream 1% maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.

At AAD 2025, UCB will present 5-year data for Bimzelx in psoriasis, highlighting rapid, durable responses and long-term safety for patients.

Charrow shares insights in complex dermatology and her work in HS at the annual meeting.